Sorafenib induces partial response in metastatic medullary thyroid carcinoma.
?
['Adult', 'Antineoplastic Agents/*therapeutic use', 'Benzenesulfonates/*therapeutic use', 'Bone Neoplasms/drug therapy/secondary', 'Carcinoma, Neuroendocrine/complications/*drug therapy/secondary', 'Humans', 'Immunohistochemistry', 'Lung Neoplasms/drug therapy/secondary', 'Lymphatic Metastasis/pathology', 'Male', 'Mediastinal Neoplasms/drug therapy/secondary', 'Neoplasm Metastasis/*drug therapy/pathology', 'Niacinamide/analogs & derivatives', 'Phenylurea Compounds', 'Positron-Emission Tomography', 'Pyridines/*therapeutic use', 'Schistosomiasis/complications', 'Skin Neoplasms/drug therapy/secondary', 'Soft Tissue Neoplasms/drug therapy/secondary', 'Thyroid Neoplasms/complications/*drug therapy/pathology']